occto
us
OXFORD COLON CANCER
TRUST
OCCTOPUS OXFORD COLON CANCER TRUST
Re8lstered tharlty no.1104702
TRUSTEES, ANNUAL REPORT AND FINANaAL STATEMENrs
YEAR TO 310ECEM6ER 2025

OCCTOPUS OXFORD COLON CANCER TRUST
TABLE OF CONTENTS
Reference and AdministratNe Details
Trustees, Annual Report
Statement of Trustees, Responsibilibe5
li
Independent Exarninerfs Report
12
Statement of Financial Actfvitle5
13
Balance Sheet
14
Statement of Cash Flows
15
Notes to the Financlal Statements
16
Page I

OCCTOPUS OXFORD COLON CANCER TRUST
REFERENCE AND ADMINISTRATIVE DETAILS
Patrons:
Professor Sir Walter Bodmer
Professor Peter Atkins
Mr Neil Ashley
Trustees:
Professor Sir Neil Mortensen (Chairman)
Ms Katherine Baker
PrOfeS￿r Christopher Cunningham
Mr Nicholas Han(ty (Trea5urerl
Mr Simon Holland
Mr Rob Jonckheer
Mr Oliver Jone5
Ms Marianne Julebin
Professor Tim Mau8han
Professor Bryan Morton CBE
Mr Mark Rowse
Dr Michael Stein
Mr Philip Williams (retired 9 June 2025)
Secrètary:
Independent Examlner:
Prlnelp•l office:
Mr Rob Jonckheer
Mr Stephen Dexter FCA
Colorectal Centre
The Surgery & Dlagnostlc Centre
Churchill Hosp¢tal
Headington
Oxford
OX3 7U
HSBC Bank plc
65 Cornmarket Street
Bankers:
Oxford
OXI 3HY
occropus Oxford Colon Cancer Trust
l July 2¢JM Inumber 11047021
http'.//bWWW.OCCtopus.org.uk
Name
Re8lstrat(on as a charlty:
Website:
Page 2

OCCTOPUS OXFORD COLON CANCER TRUST
TRUSTEES, ANNUAL REPORT
The trustees present thelr annual report and finantial statements forthe year ended 31 De￿mber 2025. The financial
statements have been prepared in accordance with the accounting policies set out on pa8es 16 to 19 and comply with
the chariW5 trust deed. the Accounting and Rep￿tIng by Chartties.. Statement of Recommended practi￿ applicable
to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and
Republic of Ireland IFRS 1021, and applicable law as discussed more fully in note l on page 16.
Oblectlves and actlvltles
The aims of the charity are to improve the dla8nosls and treatment of colorectal cancer. infiammatory bowel disease,
and bowel continence by promoting education, Innovatlon and researth as well as through the provlslon of speclallst
equipment to allow new treatments to be delr¥ered to patients.
Thls Is achièved through providing grants and equlpment to the colorectsl surgery department and Its cllnical partners
at the Oxford Unlversbty Hospltals NHS Foundation Trust I"OUH") and prowding grants to the Unlversity of Oxford and
other academk and professional instttutions. The trusteestonfirm that they have referred tothe Charity Commission's
guidance on public benefit when reviewing the tharws aims and objectives, in planning future activities, and
providin8 8rants for the year.
The charlty furthers Its charitsble purposes for the publlc benefit through tts 8rant-makln8 policy whlch looks to..
fund research related to the early dlagnosls and t￿atment of Sufferers wlth colorectal can￿r and related
condltlons
provlde support for educatlon and trainln8 in treatlng colorectal cancer and related condltlons,. and
fundlng the purchase bythe OUH of speclallsed surgical equipment for the treatment of colorectal cancer, and
inflammatory bowel conditions such as ulcerative colltis and Crohn's dlsease.
Grant rnakI￿ and fvndlry polkv
The charity has established tts grant making p)liry to athieve its objects for the publlc benefit. The ultlmate
beneficiarles of the grant making programme are those who suffer from colorettal Cancer. ulcerative colitis, Crohn's
dlsease. inflammatory bowel. bowel continence problems ènd those at risk of developing these diseases. According to
the latest data from the World Health Organisation, cancer is the second most common cause of death worldwide,
and the incidence of cancer 15 increasing in all countries. Canceraccounted for nearly 10 milllon deaths in 2020. nearly
one in six death5. The global cancer burden is experted to reach 29 million new cancer cases per year by 2040. a 60%
increase on the estimated 18.1 milllon cènors in 2018 IV4lHO Wofld Cancer Report 2022).
Colorertal cancer is the third most common cartcer in both men and women. In figures published by CRUK for the
period 2017-2019, there V￿re 44,ICKI new cases each year, and around 53% survived 10 years.
The charlty provides grants to fund postgraduate research fellowships focussed on the objective5 of the charity. The
amount and temi of the reward is decided bythe trustees based on the advice of those trustees with clinical expertise.
Typically. the research fvnding will cover a period of two years. though this may be longer or shorter at the trustees,
discretion. The beneficiaries of the fellowship5 are monttored through regular reporting to the trustee meetings on
progress.
Page 3

' OCCTOPUS OXFORD COLON CANCER TRUST
TRUSTEES, ANNVAL REPORT IcoNfiNUED)
The charity funds equipment and training for those invofved in treating medical conditions that are within the scope
of the charws work.
The charity provides one off grants for individual postgraduate research in the field of colorectal cancer and its reloted
conditions. These grants are assessed by the clinical trustees and, rf considered appropriate, are reviewed by the
trustee body who determine whether to proceed with the grant.
The charity funds the purchase by the OUH of specialised surgical equipment to expand knowledge of new and
innovative techniques that improve treatment of colorectal cancer and tts related conditions.
Any private benefflt received by research institutions. researchers and healthcare bodies is purely Incidental to the
objects of the charit￿S work.
The charity reviews the grant making pollcy annually to ensure that it reflects the charitys objects and therebv
advances public benefit.
Strurture, governance and maDwm•nt
Strurture, moftaqementand communlcatlon
The ¢harity is a reglstered charlty. number 1104702, and is constltuted under a trust deed dated 23 December 2CK)3
and by an Amended and Conformed Declaration of Trust entered into by the Trustees dated 13 March 2024.
The charit￿5 operations are controlled by the trustees. Professor Sir Neil Mortensen Is Chalrman and provldes medlcal
direction. Mr Rob Jonckheer acts as Secretary, providin8 SUPPOrt on charitsble legal, regulatory and governance
aspects. Mr NScholas Handy acts as Treasurer, provldlng support on all financlal aspects of the charitys artlvltles.
The charity has a part time communication, PR and marketing consuhant I'administratorti to asslst wlth the
administration, publicity and fund raising of the charity. who provides these servlces on a contracted basis. The
admlnlstrator ensures the charity media profile is kept up to date.
The trustees hold formal meetings at least three times a year to consider all aspetts of the charltrfs activities, and to
monitor pro8ress on the charivs strategic and operational plans (see athievements and performance below). These
plans help trustees and supporters to work towards a shared and sustainable vision for the future, agreeing priorities
and identlfylng approprlate activlties to achieve them.
A Nominations Committee. compr151ng Professor Sir Nell Mortensen and other trustees as requlred, is responsible for
recornmendatlOll5 to the trustees on the appointment of new trustees. Trustee perfomance and re-appoSntment is
considered annually. Trustees are appointed through meeting With the Nominations Committee and, where
practicable, through structured visits to the colorettal surgery department at the OUH. Trustee trainin8 IS throu8h
peer support and attendance at relevant conferences or seminars.
Communicationswith svpporters and other interested parties are condurted through various means including tailored
mailing, a quarterly newsletter, the charl￿5 webstte. Just Givin& the annual report and events such as open days at
the colorectal cancer department at the OUH. Feedbatk from supporters is solicited in personal correspondence and
communication.
Page 4

OCCTOPUS OXFORD COLON CANCER TRUST
TRUSTEES. ANNUAL REPORT (copillNVED
Governan¢e
During the year, the charity has maintained its emphasis on its own and tts partners, accountability. The trustees seek
to follow the good practlce'CharityTru5tees Gurde. issued by ICSA.. The Governance Institute.
The trustees meet regularly lat least three times a year fom)ally. additionally as needed) to revlew the status of
Inltlative5 in hand and the charitls financial and investment posrtion. These meetings are held either in person or.
where appropriate, through electronic means. The development of strategit options which could affert planning Is
also discussed.
The trustees remaln commltted to mlnimi5ing administrative costs and to monitoring the performance of initiatives
implemented in association with the OUH.
Mr Stephen Dexter FCA is the currently appolnted Independent examiner of the charity.
A¢hle¥ements and perf4rmaThce
In 2025 the tharity malntalned its fund-raising artivities in order to enable It to continue to provide grants and
resources In accordance wlth Its oblertfves.
The charity agreed to fund a new outpatient Hlth Resolutlon Anoscopy IHRAI servlce at the Churchlll Hospltal at a cost
of £70,07012024 £Nill. It is a signlficant step fonvard for the wlon. enhandng early detection and management of
anal pre-cancer and cancer. The service has helped move the care from an Inpatient general anaesthetlc to a more
comfortable local anae5thetic day case and will reduce the need to travel.
As part of the grant making process the charfty provided funds amounting to £25.0(KI12024 £30.OWl to the Royal
College of Surgeons of England to part fund a Robotics research fellowship using some of the funds provided by the
Dr Elman Poole Research Fellowship bequest.
This year the fellowship has supported the University of Oxford department of Immuno-oncology to treate a platform
allowlng Identification of novel cancer speciflc tsrgets for Immunotherapy. This was to be achieved by.- lil integratin8
exlstlng methodology for the spatial analysis of immunopeptidomes in a colorectal tancer tissue section; and lill
chararterising the spatial distribution of the tumour micro environment usin8 hi8hly multiplexed immunofluorescent
technology Itissue cytometryl. in an adj￿nt section. Together. these two approaches will provlde a detailed map of
the cancer, highlightin8 the re8ional distrlbutlon of Immunopeptides.
Durln8 the year the charlty contlnued to fund throu8h grdnts to the OUH a ainical Data Manager and Research
Facilitator (the °Data Manage￿) at a cost of £24.24512024 £23.928). The primary role of the Data Manager supports
data management. education and research in the Colorectal DepartmenL In partlcularthe Data Manager assists in the
collection, collation and dissemination of cllnital data for purposes of clinical governance and submission to national
and international audits. The Dats Manager provides dirert vislblllty of the work of the chartty within the Department.
The charity continued to fund at a cost of £lO,C(i112024 £96,912) the two year study into a potential link betsveen the
enteric nervous ￿teM and Crohn's disease with the Unlversity of Oxford Medlcal Sciences Division 1.the ENS
re5earch~l. The project investigates a potential link between the netwot* of special cells and nerves which pass
alongsSde the blood vessels to theBut. It isthought this enteric nervous system IENSI influences gut secretion, motilitv,
absorption and immune funrtion. There is some ewdence that the ENS does not perform optimally in Crohn's Disease
but thls has never been properly studied before. On the 7 January 2026 the charity agreed to contlnue this research
Page S

. OCCTOPUS OXFORD COLON CANCER TRUST
TRUSTEES. ANNUAL REPORT IcopinNUED)
under a new agreemen¢ subject to the achievement of annual milestones agreed between the charity and the
University of Oxford Medical 5cience5 Division. at an amount of £60.0(Kl per yearfor three years.
The charity also provided funding for the provisÉon of items requested by the nursing team to address speclflc Issues
identified by those nurses. In 2025 these items amounted to £1212024 £7601.
The charity measures its perforniance in two areas: in the provision of grants and the subsequent success of those
grants in achievin8 the 8rant makin8 policies. The provision of grants is monitored at each trustee meeting where the
trustees with clinical expertise will provide advice and the trustee t￿Y as a whole will confimi whether the grant wlll
be made. As eath grant provided tends to have unique circumstances the charity measures its performance on a case-
by-case basis and at trustee meetings follows up the benefits from the grants.
The charity continues to monltor and address opportunities for reseafch and the application of sur8l¢al technology In
treating colorectal cancer and its related conditions. Its priorities at present are to-
Identlfyin8 future grants and education projects
continue to ralse funds to address its charitsble objertive5: and
conseNe a fund for future technolo8ical deYelopments1see also under Reserves pollcy belowl.
The charity continues to send e-newsletters to ensure past and potentlal donors are kept upto date wlth our actlvities.
The website is re8ularty upjated to remove out of date links and to refresh content.
Fundralslng
The charity is committed to following the Fundraisin8 Regulatorfs"Code of Fundraisin8 Prartice" I'the Code") which
sets the standard5 that apply to fundraislng carried out by all charitable instltutions and third-party fundraisers in the
UK. The charity is registered with the Fundraising Regulator whlch fom)alises its commitment to follow the Code.
The charfty'5 administrator Undertakes fundraising projects in compl13n￿ with the Code. These projects include
supportinR individuals who undertake sponsored activities. This support includes the provision of entrance to the
Oxford Half Marathon and the provlsion of product5 branded with the charlty logo to IndSvlduals undertaking specific
fundralsing activlties approved by the trustees.
The charity a150 provide5 literature at the hospitals that it suP￿rtS giving contart details of the charity. The charity is
grateful for any legaties provided but is not inVo￿ed wtth the drafting of those legacies.
Prlnclpql rfsks and uncertalntles
The prlnclpal rlsks faced by the charlty have not changed significantly frorn last year,. primarily the impact of a global
pandemic. the performance of investments and operational rlsks from norkeffectNe grant makinB and the capacity of
the charity to make effectNe grants.
The impart of COVID-19 has demonstrated that a global pandemic outside the control or influence of the charity can
significantly affect the scale of its activities but not tts ability to continue to operate effectively. The trustees consider
that as the charity has minimal ongoing commitments. an established core of donors and sufflclent reseNes it can
contlnue to meet its charitable objectives for the foreseeable future.
Page 6

OCCTOPUS OXFORD COLON CANCER TRUST
TRUSTEES, ANNUAL REPORT (COPfflNUED)
The trustees consider the variabilty of investment returns on funds invested or deposited to constitute the charitws
major financial risk. This is mitigated by having a diversified investment portfolio Ithrough investing in fund51 and
monitoring the annualised returns of that investment portffolio included in the monthly management actounts, with
a formal report by the treasurer at each of the trustee meetings. This diversification is achieved through the
Investment In managed funds provided by the Charities Aid Foundation ICAFI with an approprlate mix of Equity and
Fixed Interest investments.
The operational rlsk from research and grant awards is that they may be non-effective in advancing knowledge and
prartice to those treating colorectsl cancer and related conditions. This is managed through retaining trustees who
are cllnlcal experts to whom the redpients of the awards provide regular and detailed report5. In addition, the
reclpients provide re8ular reports to the trustee body as a whole. The process of reporting and review assists us, and
those we support, in keepin8 track of how research and knowledge is developirvJ. This review process also focuses on
the public benefit derived from our funding of their work.
The operatlonal rlsks from the fundln8 of speclallsed sur86cal equlpment forthe use by the OUH are:
the sur8lcal equlpment may be non-effertlve In treatlng the speclallsed conditlon of colorectal cancer and
related conditlons
the surgical equipment could be procured by the Natlonal Health servi￿ as part of its nomal spendin8 and
does not therefore meet the charitvs aim of innovative technique5,' and
the surglcal equipment might be approprlated by other areas of the OUH whlch, whllst provldln8 a publ1¢
benefit. would not necessari￿¥ achieve the chariVs aims.
The operatlonal risks from the fundln8 of speclallsed surgScal equlpment a￿ managed by the appolntment of cllnlcal
experts as trustees who advise the trustee5 a5 a whole on the efficacy of the equlpment and Its Innovative natu￿. The
cllnical experts, as the primary usets of the equipment provide assuran￿ that the equipment is not appropriated by
others. All funding grants for specialised sur8ical equlprnent are agreed by the tnistee body as a whole to ensure the
r15ks noted above are appropriatefy managed.
Flnanclal re¥le••
The princlpal funding sources of the charrty is made up of corporate entlty donations (typically in respect of restrlrted
fundlng of projects) and individual donations (typically from patients of the OUH or their relativesl together with 8ift
aid where the donor has provlded the appropriate dedaration.
In addition, events may be held to raise fvnds where income is generated both by the sale of tkkets to the event and
charity auctions or other donations provided during the event.
Where donations exceed the immediate funding requirements of the tharity the excess is invested in interest bearing
bank accounts or investments in accordance with the investment policy (see below) and the dividends and interest
from these investments provides funding for the charity.
The grant making actiVFty is discussed in detail in the "Achievements and Performance. section of the report above.
Durlng the year, the charity received £18.641 of unresuicted non-recurrlng donations12024 - £9.6621 and £720 of
unrestricted recurring donations 12024 £7201. including relevant gift ald. Investment Income, all of which was
unrestrlcted. amounted to £9,09312024 £13.6921.
Page 7

OCCTOPUS OXFORD COLON CANCER TRUST
TRUSTEES. ANNUAL REPORT (CONTINUED)
As part of its fund raising activities the charity received £12,022 in sp)nsorship income from participants in the Oxford
Half Marathon12024 £3.3291
The charity continued rts commercial agreement wrth Everyclick where Everyclick makes a payment to the charity In
return for being able to list that charity on their services and to use the charl￿$ trade mark for the services. £2 of
income was received in re5pert of this12024 £21.
The Data Manager, employed by the OUH and funded throu8h a grnnt by the charity of £24.24512024 £23,9281,
supports an established research tearn of dinicians. speciallst nurses and research nurses to artively initiatei promote
and drtve the recrultment of OUH patlents for induslon In natlonal and Intemational clinical trials.
The charity agreed to SUPPOrt the role of an additional research nurse at the Translational Gastroenterology and Liver
Unit which is part of OUH focused on research and clinlcal care related to gastrointestinal and liver disease5, workin8
to translate s¢ientrficfindings into new and better clinical treatments. Should OUH continue the postfor a second year,
Ocrtopus would donate up to £59,547 to OUH towards funding that second year.
The charlty agrèed to fund a new outpatlent Hlgh Resdution Anoscopy IHRAI seThlce at the Churchill Hospital at a cost
of É70,07012024 £NIII.
As the chartty ha5 no employees ft ha5 no ernplo￿ent or penslon obligatlons.
The overall result of the actlvlty durlng the year was a deficlt for the year of £79,11012024- deflclt of £155,205> of
whlch £24,119 was represented by net galns on Investments12024- Gains of £25.0831.
The balance of fvnds decreased to £423.847 at 31 December 2025 from £502,957 at 31 December 2024. Total funds
included a surplus of £72,29512024- £97,223) of restricted income funds Unrestricted funds amounted to £351,552
12024- £405,734). Further detai15 are discussed In the reserves wllcy sectlon which follows.
As noted in the reserves policy section which folk*WS the tharity has sufficient reserves to fulfil Its commltments.
Investments and Investmentpolky
The trustees review the investment wlicy on èn annual basis to ensure that it refiects the needs of the chartty. The
objertive of the p)licy is to invest funds that are not anticipated to be used within the next 12 months.
The tru5tee5 hove approved a Treasury Policy where cash antlclpated to be required within the current and followin8
months should be held in Instant 3ccess accounts provlded by the charivs bankers. It is at the dlscretlon of the
treasurer as to how much should be held in an interest-bearin8 account. In determining the anticipated requirement,
the most recent approved budget or reported latest estimate should be the basis of the assessment.
Cash not anticipated to be required within the nexttwo years should be held in a portfolio of Equity and Ftxed Interest
nvestments held wlthln a Fund avallable whhln the IFSL CAF portfolio. The trustees determined. based on the advlce
of the treasurer, that the IFSL CAF ESG Income and Growth Fund met the investment objectNes of the charity.
The aim of the IFSL CAF ESG Income and Growth Fund is to InC￿aSe the value of an investment over a minimum of
five years through a combination of capitsl growth - which 15 profit on investments held, and income received by the
Fund - which is money paid out of investments, such as dividends from sha￿$ and interest from bonds. The Fund also
aims to deliver, over any rolling five year period, an average of inflation plu5 3% per annum. The Investment Manager
Page 8

OCCTOPUS OXFORD COLON CANCER TRUST
TRUSTEES, ANNUAL REPORT ICONTINUED)
seeks retums by investing in companies that are focused on driving and improving E5G change and are a150 well
posltloned to grow proflt and overall company value.
Investments are Shown in the balance sheet at rnarket value of £346,461 at 31 December 202512024- £322.342).
Cash balances at the end of the year5tood ot £150,52412024- E226.2831 of whbch £22.59412024- £22.2311 wa5 held
in an interest-bearin8 account.
The galns arlslng during the year from the revaluatlon of the chariV5 investments were £24.11912024 gains of
£25,083). Investment income from Investments and interest was £9,09312024- £13,6921.
A recent Fund Managerf5 report (issued in respect of the quarter ended 30 September 20251 relatlng to IFSL CAF ESG
Income and Growth Fund, Stated:
"Market Commentary
At a glance
Global equltles rallled In Q3. driven by strong eamings and Al momentum
Fed cut rates for the flrst tlme thls year, s18nalling a dovish pivot
Inflation pressures re-emerged due to tariffs, but employment remalns the Fed's key concern
Equities & Bonds
Al-led tech stotks powered US markets hl8her, with Chlna. Japan. and the UK also postlng solld gains. Europe
underperformed, dragged down by polrtical instabiltty in France. Globalty. equities benefited from robust earnings,
easing trade tensions, and falllng US b)nd yields. The Fed's September rate cut- its first this year- highli8hted growing
concerns over a softenin8 I1￿￿T market. Shortdated bonds outperformed, whlle long-dated government bonds saw
mlxed results.
Al & Earnln8S
Corporate earnings were buoyed by a88ressive Al investment. Tech glants - Alphabet, Amazon, Apple. Meta. and
Microsoft- collectively spent over $92 billion in Q2. a 68% year-on-year inttea5e. These inve5tsnents, larger than the
GDP of many mld-si2ed nations, underscore the scale of the Al ra￿. While the long-term revenue impart remains
uncertaln, the short-term boost to sentiment Is clear.
Bond Market Moves
Two-yearTreasury yields peaked near 4% in July before retreating to 3.6% by quarter*nd. The 10-year yleld followed
similar path, dropping from 4.48% to 4.15% after the Fed's rate cut. In contrast, long-dated US bonds were flat.
Globallys yields on longer maturitles rose, particularly in France. where budget tens￿n$ tri88ered a cabinet reshuffle-
hlghlighting the political challenges of f15cal tightening.
Q4 Outlook
As we enterthefinal quarter, key watchpoints indude central bank rate decisions. the durability of corporate e3min8S.
and geopolltlcal fla5hpoints- especially in Europe and the Middle East. A successful and more enduring result of tarlff
negotiations with major tradin8 partners like China will colour the ba(*drop of global markets toward year-end.
Investors will be watching for signs of economic resilience. inflation moderatKin, and fiscal clarty."
The chariws investment perfomiance over 2025 has refiected the turmoil in the markets throu8h the year. with a
year-end overall positive return of 10.2% induding dividend income received12024 - negative return 8.0%). The
Page 9

OCCTOPUS OXFORD COLON CANCER TRUST
TRUSTEES, ANNUAL REPORT (CONTINUED)
trustees have been carefully monitorin8 the situation as it has develo&*d over the year and have taken the view that
in the lon8-term funds not specifically required withhn a year have the best probability of exceedlng inflation bv
retaining the Investments in their cuThent funds. No additional investments were made in the year.
The trustees continue to monitor returns on a Month￿ basis and still consider that on a long-temi basis the current
investment policy remains appropriate to generate a return over the life of the investments in excess of inflation.
raxatlon
The charity is entitled to those exemptionsfrom UK taxation which are available in law to charf(ies.
Reserve5 polky
The trustees. polTrcy Is that so far as possible the annual Income of the charity should be applled exclusively towards
Its charltable artivltles, as at present It has minimal adminlstratlve expenses. However, the trustees reco8nise that
reserves will fluctuate, as its income in any year is to a large extent unpredictable and unlikely to match precisely
opportunitles for expenditure to meet its objertives.
The balance of funds at the 31 December 2025 amounted to £423￿7{20z4- £502,957) of which:
£60,00012024- £85,0(Kil restricted to the Dr Elman Poole Research Fellowshlp
£10,05412024 - £10,0541 restrlcted to the Exosome Projects
£2.24112024- £2.1691 was restritted to supporting the stoma and colorectal nursing teams In Oxford,
The balance of £351.55212024- £405.7YI} was unrestricted.
As noted above and In note 14 below there Is a potentSal contlnuatjon of the ENS project at an amount of £60.C()O per
nnum for three years and an additional research nurse at the Tran51attonal Gastroenterolo8y and Liver Unlt at
potential cost of £59.547. Over the nèxt year these t￿ntIal liabilities could amount to a maxlmum of £119.547.
The balance of £232,005 Is considered a free feseNe and s avallable to pmwde 8rants that meet the charit￿S policles.
Remunen7tlon polky
The trustees consider the board of trustees as comprising the key management personnel of the charity in charge of
directing and controlling the charity and running and operating the charity on a day-to4ay basis. All trustees give of
thelr time freety and no trustee rernvnerat￿n or expenses were paid in the year.
Trustees are required to disclose all relevart interests and register them with the Chaiman and in accordance with
the charivs policy withdraw from decisions where a conflict of interest arlses.
Page 10

OCCTOPUS OXFORD COLON CANCER TRUST
STATEMENT OF TRUSTEES. RESPONSIBIUTIES
The charity trustees are responsible for preparing a trusteg annual report and financial ststements In accordance
wlth applicable law and United Kingdom Accounting Stsndards Iunited Kingdom Generally Accepted Accounting
Practlce}.
The law appltcable to charities in England and Wales requires the charity trustees to prepare financlal statements for
each year whlch Elve a true and fair view of the state of affairs of the charty and of the Incomlng resources and
applbcatlon of resources. of the charity for that period. In preparing the financial statements, the trustees are required
to:
select sultable accounting policies and then apply them consistentlv
observe the methods and principles in the applicable Charities SORP
make judgements and estimates that are reasonable and prudent
stste whether applicable accounting stsndards have been followed, subject to any material departures that
must be disclosed and explained in the financial statements- and
prepare the flnanclal statements on the going concern basis unless It Is Snapproprlatè to presume that the
chartty wlll continue in business.
The trustees are responsible for keeping properaccountin8 rrfords that disdose with reasonable accuracy at any tlme
the flnancial position of the charty and to enable them to ensure that the finandal Statements comply wlth the
Charities Act 2011, the appllcable Charltie5 (Accounts and Reports) Regulatlons, and the provlslons of the Trust deed.
They are a150 responsible for safe8uardin8 the assets of the charrty and taking re850nable steps for the prevention and
detectlon of fraud and other irregularities.
The trustees a￿ responsible for the maintenance and integrity of the charity and flnancial Infomiatlon included on
the charlty's webslte In accordance wlth le8lslatlon In the United Kingdom governln8 the preparation and
di55emination of financlal statements.
Approved by
trustees on 18 March 2026 and slgned on their behalf by:
Professor Slr Nell Morte
sen
Oxford
Page 11

OCCTOPUS OXFORD COLON CANCER TRUST
INDEPENDENT EXAMINER'S REPORT
to the Trustees of the Ocrtopus Oxford Colon Cancer Trust
I report on the accounts of the OcttOPUS Oxford Colon Cancer Trust forthe year ended 31 December 2025, whlch are
set out on pages 13 to 25.
Respectlve responsibilities of trustee5 and examlner
The charltvs trustees are responsible for the preparation of the attounts. The Charl￿strUstees consider that an audit
is not required for this year under section 144121 of the Charities Act 2011 (the 2011 Act), and that an independent
examination is needed.
It Is my responsibllity to..
examlne the accounts under section 145 of the Charities Act:
follow the procedures laid down in the general Dlrertions gfven bythe Charty Commission (under sertion 145
15llbl of the 2011 Artl,. and
state whether particular matters have come to my attention.
Basls of Independent examlnerfs stateme
My examlnatlon was carried out In accordance with the general Dlrertions given by the Charity Commission. An
examinatlon include$ 3 revlew of the accounting records kept by the charity and a comparison of the accounts
presented with those records. It a150 Includes consideration of any unusual items or dlsclosures In the accounts and
seeking explanations from you as trustees concerning any such matters. The procedu￿$ undertaken do not provlde
all the evidence that would be required In an audit and consequently no oplnlon Is 8lven as to whether the accounts
present a'true and fair vlev/. and the report 15 limited to those matters set out in the next statement.
Independent examlnerfs statemènt
In connection wth my examination, no matter has come to my attention:
111 which gives me reasonable cause to believe that in. any material respect. the requirements..
to keep accountin8 records in accordance with section 130 of the 2011 Act;
to prepare accounts which accord with the accountir8 records and comply with the ac¢ountin8 requirements
of the 2011 Act
have not been met- or
121 to which, in my opinion. attention should be drawn in order to enable a proper understanding of the accounts to
be reached, other than Note l on page 16 which state5 that the financial statements have been prepared to give
'true and fairf view and have departed from the Charities IAcrnunts and Reports) Regulations 2LIJ8 only to the
extent required to provlde a 'tnse and fair vie￿. This departure has involved following Accounting and Reporting
by Charitles preparin8theiraccounts in accordantewith the Flnancial Reporting standard appllcable In the UK and
Republic of Ireland IFRS 1021 issued on 16 July 2014 rnther than the Accounting and Reporting by Charities..
Statem
nt of Recommended Practice effectNe from l April 2￿5 which has since been withdrawn.
Stephen Dexter FCA
Grove
18 March 2026
Page 12

OCCTOPUS OXFORD COLON CANCER TRUST
STATEMENT OF FINANCIAL AcnvmES
For the year ended 31 December 2025
2025
2024
Restrirted
Not• Incom• Uniestrkted
T¢)tsl
Re5tActed
Income
Unrestrirt•d
Total
Inwme and endowments from:
Donations and le8a¢ies
Other trading actlvltles
Investments
88
19,361
12.024
9,093
40.478
19,449
12.024
9.093
40,566
2,723
10,382
3,331
13,692
27,405
13,105
3,331
13.692
30.128
Total
2,723
Exp•ndltur• on:
Ralsin8 funds
Charltable actlvlties
Totsl
N•t •xp•ndlturn and n•t
movement In funds before
g•lns •nd losses on Investments
14,464
104,315
118,779
14,468
129,327
145.795
59
13,827
125,770
139,597
13,886
196,530
210,416
25.012
25.016
70,760
70.819
124.928)
178,301) 1103.2291 168,0961
1112,1921 1180,2881
Net galns on Investments
N•t Movement In funds
R•¢on¢lllatlon of funds..
24,119
24.119
{54.1821 179,1101 168,0961
25,083
25,083
187.1091 1155,205)
124.9281
Total funds brou8ht forward
Total funds urrled forward
12
97,223
72,295
405.734
351.552
502,957
423,847
165,319
97,223
492,843
405.734
658,162
502,957
12
The notes at pages 16 to 25 form part of these accounts.
Page 13

. OCCTOPUS OXFORD COLON CANCER TRUST
BALANCE SHEEr
At 31 December 2025
2025
2024
Restricted
In¢¢me Unrnstrirted
Restricted
Income
Total
Total
Note
Unrestrlcted
Flxed assets
Investment5
346.461 346,461
322.342
322,342
Current a￿ets
Debtor5
Cash
Tot•1 current assets
Current Ilabllltl•s
Credltors and accruals
4.135
78.229
82,364
4.135
150,524
154,659
1,803
89,060
90,863
1,803
226,283
228,086
72.295
72,295
137.223
137,223
io
li
77.273
5,091
77.273
77,386
40.OIXI
97,223
7,471
83.392
47,471
180.615
N•t ¢urr•nl •ss•ts
72,295
Not Ass￿$
72,295
351,552
423,847
97,223
405,734
502.957
The Funds of the Ch•rSty
Total Income
12
72,295
351,552
423W7
97,223
405,734
502,957
The notes at pages 16 to 25 form part of these accounts.
Approved
e.trust
18 March 2026 and signed on their behalf by-
Professor Sir Neil Mort
fl5en
Page 14

OCCTOPUS OXFORD COLON CANCER TRUST
STATEMEKf OF CASH FLOWS
For the year ended 31 December 2025
2025
2024
Restrlcted
Income
Note Incorne unrestricted
Total
Unrtstrlcted
Total
C•shflows from Operatlnq
Artlviti•s:
Net cash (Ltsed Inllprovided
by operating activities
Cash flows from Inv•stln8
•ctlviti•s:
Proceeds from sale of
Investments
Dlvldends and Interest from
Inve5trnents
13
164,9281
119,9241 184,8521 128.0961
1148,8321 1176,9281
180,000
180,000
9,093
9.093
13,692
13,692
Change In cash and ￿$h
equlvalents In the year
Cash and eash equlvalent brou8ht
forward
Cash and ¢ash equlvalent carrled
forward
(64,9281
(10.8511 175.7591 128.096)
44,860
16,764
io
137,223
89.060
226.283
165.319
44,2CN)
209,519
io
72.295
78,229
150,524
137,223
89,060
226,283
The notes at pages 16 to 25 fom) part of these accounts.
Page 15

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL STATEMENTS
for ihe year ended 31 December 2025
AccounttnB polkle5
(o) Basi5 of prept7ration and ossessment of going concern
The finantlal statements have been prepared under the htstorlcal cost convention with items recognised at cost or
transartion value unless otherwise stated in the relevant notelsl to these accounts. The flnancial statements have
been prepared in accordance with the Statement of Recommended Practlce: Accounting and Reporting by Charities
preparing their accounts in accordan￿ with the Financial Rewrting Standard applicable In the UK and Republic of
Ireland IFRS 1021 issued on 16 July 2014 and the Financial Reporting Standard applicable in the United Kingdom and
Republic of Ireland IFRS 1021 and the Charities Art2011 and UK GenerallyAccepted Prartice as it applies from l January
2015.
The flnancial statements have been prepared to glve a 'true and fairf view and have departed from the Charltles
(Accounts and Reports) Regulations 2cNJ8 only to the extent required to provide a 'true and fair vie￿. This departure
has Involved followlng Accountlng and Reportlng by Charitles preparlngtheir accounts in accordance with the Financial
Reporting Standard applicable in the UK and Republlc of Ireland IFRS 1021 issued on 16 July 2014 rather than the
Accounting and Reporting by Charities.. Statement of Recommended Prartice effective from l Aprll 2005 whlch has
since been withdrawn.
The charity constltutes a public beneflt entlty as defflr￿d by FRS 102.
The trustee5 considerthatthere are no material uncertaintiesabout the charirfsabllityto continue as a goingconcern.
With respect to the next reportlng perSod, 2026, the most significant areas of uncertainty that affect the carrying value
of assets held by the charlty are the level of investment return and the performance of investment markets (see the
Investment policy and risk mana8ement sections of the trustees, annual report for more Information).
(b) Funds strutture
Restricted funds are funds whlch are to be used in accordance with specific restrictions Imposed by the donor or
through the temis of specific appeals.
Unrestricted Income funds comprise those funds which the trustees are free to use for any purpose in furtherance of
the charltable oblerts.
(c) Income recognltlon
All income is recognised once the charity has entitlement to the ineome, It Is probable that the income wlll be received
and the amount of income recelvable can be measured reliably. Donations are recognised when the charity has been
notified in writing of both the amount and Settlement date, ora cheque has been received. In the eventthat a donation
is subject to conditions that require a level of perforniance before the charity is entitled to the funds, the Income is
deferred and not recognised until either those conditions are fully met. or the fufftlment of those condition5 15 whollv
wlthin the control of the charity and it is probable that those conditions will be fulfilled in the reporting period.
Legacies are reco8nised on a case by case basisfollowin8 the grantingof probate when the adminlstratorlexecutor for
the estate has communicated in writing both the amount and settlement date. In the event that the gift 15 in the fomi
of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the
Page 16

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL sfATEMEKrs
fiyr the year ended 31 December 2025 {Contlnuedl
value of the gift being reliably measurable with a degree of reasonabte accuracy and the title to the asset having been
transferred to the charity.
Interest on funds held on deposit is included when receivable and the amount can be measured rellably bythe charlty;
this is nomially upon notiftstion of the interest paid or payable by the bank.
Dlstrlbutlons are recognlsed once the dlstrlbutlon has been declared and notlflcatlon has been recelved of the
distrlbutlon due. This Is nornially upon notification by the fund manager.
Id) Expenditure recognition
Liabilitles are recognised as expenditure as soon as there Is a legal or construrtive obligatlon commltting the ch3rlty
to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured
rellablv.
All expenditure is accounted for on an accrua15 basis. expenses induding sUPPOrt Costs and govemance costs are
allocated or apportioned to the applicable expenditure headings. For more infomiation on this attributlon refer to
note (fj below.
GrAnts payable are payments made to third parties in the furtherance of the charitable objects of the tharity. In the
case of an uncondltional grant offer this is accrued once the recipient has been notified of the grant award. The
notlflcatlon 8lves the reclpient a reasonable expectation thatthey will recefve the on&year or muki-year Brant. Grants
awards that are subject to the recipientfulfilling performance conditions are only accrued when the recipient has been
notified of the grant and any ￿ma[nIng unfvlfilled Condition attKhing to that grant Is outslde of the control of the
charity.
ProvlsSons for grants are made when the intention to make a grant has been communicated to the recipient but there
is uncertainty as to the timin8 of the grant or the amount of Brant payable.
The provlslon for a multl-year grant15 reco8nlsed at its present value where settlement Is due over more than one
veaT from the date of the award. there are no unfulfilled perfomance conditions under the control of the charity that
would permit the charity to avoid making the future paymentlsl. settlement 15 probable and the effert of discounting
Is material.
The dlscount rate used Is the average rate of investment yield in the year in which the grant award is made. Thls
discount rate is regarded by the trustees as providing the m05t current available estimate of the opportunlty cost of
money reflectlng the time value of money to the charity.
fe) Irwoverable VA T
The charity is not registered for VAT so irrecoverable VAT Is charged against the expenditure heading for whlch rt was
Incurred.
ffJAllocotion of supportand governonce costs
The Charity has no specific governance costs, whlch tomprise all costs involving the public accountability of the ch3rity
and its compliance with regulation and Bood practice. as there are no trustee costs and the Independent Examiner
Charges no fee5 for the examination. Other support costs in respert of charttable activities have been apportioned
Page 17

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 t>etember 2025 (Contlnued)
based on an assessment of the Individual cost and related activity it supwrts. The allocation of support and
governance costs is explained In note 6.
(g) Costs of raisingfunds
The costs of generatlng funds conslst of the allocation of support costs identified as directly related to the cost of
generating funds and the costs of specific events whose purpose is to raise funds.
fh) Choritoble ortivities
Costs of charitable aciivitles include grants made. surgical equipment provided and an apportlonment of support costs.
(IJ Flxed asset Investments
Investments are a fom of basic financial instrument and are initially recognised at their transaction value and
subsequently measured at their fair value as at the balance sheet date uslng the closlng market price. The statement
of flnanclal artivities includes the net gains and losses arising on revaluation and disposals throughout the year.
The charity does not acquire put options. dÈrlvattves or other complex financlal Instruments.
The maln forni of fFnancial rfsk faced by the charity is that of volatility in equtty markets and investment markets due
to wlder economlc condltlons. the attitude of investors to investrnent risk and changes in sentiment toncernln8
equltles and withln particular 5ertors or sub sectors.
J Investment goins and losses
All galns and losses are taken to the Statement of Flnandal Attlvfitles as they arlse.
Galns and losses are calculated as the difference between the fair values * the current and prevlous balance sheet
dates or, if purchased or sold during the year, the difference between fair value at the balance sheet date the asset
was held and the purchase price or sales proceeds
Ikj Penslons
The charlty has no employees and no pension obli8ations.
(IJ Debtors
Oebtors are recognised at theSr recoverable amount (the amount the charity anticipates it wlll recelve from a debt or
the amount it has paid in advance for goods and services).
(m) Cosh ot bonk ond In hond
Cash at bank and in hand is held to meet short term cash commitments as they fall due. Cash equivalents are short
term highly liquid investments readi￿ convertible to known amounts of cash and are subject to an insi8nificant change
in value. A cash equNalent has a short temi maturity which is not expected to exceed three months.
Page 18

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL sfATEMEpirs
for the year ended 31 De¢ember 2025 (Continued)
(n) Liabilities
Liabilities are amounts due to creditots and any provision made as è result of an obligation to transfer economic
beneflt. nonnally as a cash paymenL to a third party- A liability is recognised as the amount thatthe charity anticipates
it wlll pay to settle the obligation or the amount it has re￿Ned as an advanced payment for goods or services it must
provlde.
(o) Continqent liobilities
A contingent Ilability is identlfled and dlsclosed forthose grants resultlng from-
a posslble obligatlon whlth wlll only be conflm)ed by the ocCur￿nte of one or more uncertain futu￿ events
not wholly within the trustees. control,. or
a present obligation following a grant offer where settlement is elther not consldered probable,. or
the amount has not been communlcated in the grant offer and that amount cannot be estimated feliably.
Related party trnrnsactlons and trustee< remunerat11￿ arbd expenses
The trustees all give freely theirtime and expertlse without any fomi of remuneration or other benefit in cash or kind
12024 £NIII.
The trustees have made no claims for expense5 during the year12024 £Nil).
Professor Chrlstopher Cunnln8ham, Mr Ollver Jone5 and Ms Katherlne Bakerare dlrertlyemployed by. and hold senlor
positions at, the OUH which the tru5tee5 ￿nsider to be a related party. Professor Slr Neil Mortensen is an Honorary
Consultant Surgeon at the OUH and was President. Royal College of Surgeons of England.
Donatlons and legades
2025
2024
Restrkted
IN￿Me Unrestrfrted
Restrirted
Income
Totsl
UDr•strfrt•d
Total
Recurrtng donatlons
Under gift aid
Not under Bift aid
Tax recoverable
480
480
480
120
120
120
120
120
120
120
120
720
720
720
720
Other donations
Under gift aid
Not under 8ift aid
Tax re¢overable
9.241
8,987
413
9,241
9.062
426
8,420
992
8,420
3,617
348
75
2.625
98
13
250
88
18.641
18,729
2.723
9,662
10,382
12,385
13,105
Total donations
19.361
19A49
2.723
Page 19

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL 5fATEMENTS
for the year ended 31 December 2025 Icontinued)
Other tradlng actfvltles
2025
2024
5ponsor5hip
Licence fee income
12,022
3.329
12,024
3,331
Other trading artivities were unrestrirted.
Investment Income
2025
2024
Fund dlstrlbutlons
Interest on bank deposlts
8.730
363
13.269
423
9,093
13,692
Investment Income was unrestrlcted.
Allocatlon of governance and support eosts
All governance artivities are carrfed out by the tru5tee5 or the independent examlner and as they are r￿t remunerated
and have claimed no expenses the governance c05ts are £NII12024- £Nill.
The allocation of support costs between expenditure on an activity basls Is shown In the tsble below..
Cost Typ¢
R•lsln8 funds
ch•rtt•ble
•rtl¥ltles
Don•tlons and l•g•cies
Educ•tlon
and tr•lnlni
U￿r￿rI£t•d
in¢om•
fun
incom• funds
Basls
rimè s
Actual cost
Actual cost
Actu31 tost
AdmlnSstrator's cost
Just Giving charges
Web slte maSntenance
Printing and statlonery
IcKJ%
loo%
loo%
tnt
The time spent by the Administrator wa5 alk)cated between the various activities based on an assessment of the time
taken in undertaking those activities
Page 20

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL sfATEMENTS
for the year ended 31 December 2025 (Continu￿)
ExpendFture on raising funds
ZQZ5
2024
Restrirted Nursing fun(ts
Donatlons and legacies
Just Glvlng charges
59
59
Unrestricted funds
Donations Ind le¥acle5
Administrator costs
Bank and Just Glvin8 charges
Advertlsln8 and Publi¢lty
Web glte development
Printin8 and stationery
Insurance
Regulatory and assoclatlon Costs
10,427
770
12,174
721
1,593
664
183
183
85
13.033
13,827
other trndln8 •Ctlvitl•$- fvndr4lslni ￿ents
JustGiving charges
Sponsored actlvitles
Admlni5trator recharges
365
1,066
1.066
1.431
14,464
13,827
Page 21

. OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2025 Icontlnued)
8. Expenditure on charitable activities
20Z5
2024
Restrkted
Income Unrestrirt•d Total
Restrfcted
Income
Unrestrlcted
Total
Restrirted fund$
Funding research fellowshlp
Grant fundln8
Enterlc Nervous System IENSI
in Crohn's dlsÈas*
Indlvidual projects
25,000
25.lJ(Kl
70.otyj
70,000
10.000
io.c
96,912
96,912
iO,OCM)
10.000
96,912
96,912
Medli•l support
Stoma team and ¢olorerfal
nurslng staff
12
12
760
760
12
12
760
760
Educatlon and tralnlng
ClSnlcal Data Mana8er and
Research Facilitator
Other grants
24.245
70,070
94.315
104.315
24.245
70,070
94,315
129,327
23,928
4,930
28,858
125.770
23,928
4,930
28,858
196,530
25,012
70.760
Flxed asset Investments
2025
2024
Movements In Investments comprlsed:
Falr value at the beglnnlng of the year
Dlsposal
Net galns
Falr value at the end of the year
322,342
477,259
1180,0001
25.083
322,342
24,119
346.461
Investments •t falr value comprlsed:
Market Valu•
Sale •nd
Revaluation Purch￿•
2025
2024
IFSL CAF ESG Income and Growth Fund Income
346A61
24.119
322.342
Fixed asset investments were unrestrirted.
The significance of financlal Instruments to the ongoing financial sustainabllity of the charity is considered in the
financial review and investment policy and performance sections of the trustees. Annual Report.
Page 22

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL StATEMEKts
for the year ended 31 December 202S {Continuedl
The main risk to the charity from financial instruments lies in the perfomiance of the instruments and the liquidity
risks relating to the instruments.
Liquidity risk is assessed to be low as all assets are regulated by the The charity's investments can be traded
through Investment Fund Servits5 Ltd with settlement typical￿ within six days and consequently have good liquiditv.
The charlty has no Investment holdlngs In markets subject to exchange controls or tradlng restrictlons. The charity
manages these Investment rlsks by operating an investment policy that provides for diversification of holdings
between income and equty funds. The charity does not make use of derivatives and similar complex financial
instruments as it takes the view that investments are held for their longer temi totsl retum.
10. Current assets
2025
2024
R•strkt•d
Income Unrestrlrted
Restrlrted
In￿rne Unr•5trlct•d
Tot•1
Total
Debtors and prepayments
Current account
4,13S
55.635
22,594
78,229
82.364
4,135
127,930
22,594
150,524
154,659
1,803
66,829
22.231
89,060
90,863
1,803
204,052
22,231
226,283
228,086
72,295
137.223
Deposlt account
Cash at bank
72.295
72.295
137,223
137,223
Cash at bank balances are the sole components of cash and cash equlvalents. The charity has no debt.
11. Credltors falllng due wlthln one year
2025
2024
Restrfcted funds
Fundlng research fellowshlp
Unrnstrlcted funds
Administrators charge5
cisnlcal Data Managèr and Research Facilitator
Costs
Accruals and deferred Income
Other credltors
700
7.126
6,693
70,147
77.273
78
7.471
Page 23

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL STATEMEMtS
for the year ended 31 December 2025 Icontlnued)
12. Analysls of fund movements
Balance
carri•d
forward
Balance
carried
forward
Type R or
UR.
G•lns and
losses
Fund names
Income
Expendiwre Tr•nsfe
Dr Elman Poole
Research
Fellowship
Exosome Projects
Nurslng team
Support
Re5trlcted Income
Unrestrlcted
85.CM)O
10,054
125.0ty)1
60,0￿)
10,054
2.169
{16}
97,223
125,0161
405,734
40,478
1118.7791
Total
502.957
40.566
{ 143,7951
* Key.. R. restrtcted IncorneAunds, including spec￿1 trusts, of the chority,- ond U- unre5trKtedfvnds
2,241
72,295
351,552
423,847
88
24,119
24.119
Purpose and Restrlctlons
Dr Elman Poole
Re5ear¢h
Fellowshlp
Exosome Projects
A legacy from the late Or Elman Poole to fund a research fellow to pursue the
oblects of the charfty
A le8ary from the late Dr Elman Poole to fund researdi prolects Into exosomes and
related re5ear¢h.
Enhanced post ￿r$try care support for the stoma and tolorectal nursln8 team at
the Oxford Unlverslty Hospltals NHS Foundatlon Trust.
Any actlvlty of the charlty as approved by the trustees and In accordance wlth the
alms and objertlves of the charity.
Nursln8 team support
Unrestrlrted
Page 24

OCCTOPUS OXFORD COLON CANCER TRUST
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2025 Iconlinued)
13. Reconclllailon of net movement tn fvnd5 to net cash fl¢>w from opelatlng acti¥itie5
2025
2024
Restrirted
Income Unrestrlcted
Total
Income Unrestrlrted
Totsl
Net movement in funds {•s
per the statement (rf
flnanclal actlvltles)
Dlvidends and interest from
Investments
124.9281
154.182) 179.1101 168,0961
187,1091 1155,2051
19.093) { 9.093)
113,6921 113.6921
Galns on Investments
124.1191 124,1191
125,0831 125,0831
Increase In debtors
Increaselldecreasel Sn
creditors
12,3321 12,3321
13411
13411
{ 40,0001
69,802
29,802
122,6071
17,393
N•t c•sh lu$•d Inllprovlded
by op•r•tlni •rtlvltles
164.928}
119.924} 184.8521 128.0961 1148.8321 1176,9281
14. Contlngènt Ilabllltles
The charity agreed to support the role of an additional research nurse at Translational Gastroenterolo8y and Liver
Unit which is part of OUH focused on research and clinical care related to gastrointestinal and liver diseases, workin8
to translate sclentlflc flndlngs Into new and betterclinical treatments. should OUH continuethe postfor a second year,
Ocrtopus would donate up to £59,547 to OUH towards funding that second year.
Pa8e 25